KBP Biosciences Meets Primary Endpoint for BLOCK-CKD Phase 2b Study of KBP-5074 for the Treatment of Uncontrolled Hypertension in Advanced Chronic Kidney Disease Patients

The pharmacology experimental platform allows KBP to identify and progress those
products with significant differentiation.
View recent and past KBP stories,
including press releases and media coverages.
KBP is a world-class biotechnology research & development organization dedicated to providing innovative therapies for unmet medical needs.
Our integrated discovery and development platform enables us to efficiently bring new drugs from bench to clinics around the world.